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Abstract: Medical devices may revolutionize the management of acute ischemic stroke and 
prevention of recurrent events. By comparison with pharmaceuticals, the device approval process 
and subsequent application of these devices in stroke treatment is founded on a paucity of Class 
I evidence-based clinical trial data. Thromboembolectomy for acute stroke, stenting of cervical 
or cerebral arteries for stroke prevention, and percutaneous closure of patent foramen ovale 
for prevention or recurrent cerebral ischemia are being done with an ever-increasing frequency 
despite few, if any, randomized clinical trials to conﬁ  rm the appropriateness of the interventions. 
The current basis, or lack thereof, for these interventions for cerebrovascular disease is therefore 
discussed. As such, a critical appraisal of the available clinical data does not support widespread 
use of medical devices at this time outside of well-designed clinical trials.
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Introduction
The FDA approval process for medical devices is signiﬁ  cantly different than the 
process for approval of new drugs or new indications for drug (Wright 2002; Devo 
2004; Becker and Brott 2005; Furlan and Fisher 2005). For drugs, clinical efﬁ  cacy 
and safety data are mandated and usually requires 2 randomized trials though in 
certain speciﬁ  c instances (ie, very robust or large studies) one randomized trial may 
be sufﬁ  cient. However, approval of devices is typically governed by demonstration 
of ‘substantial equivalence’ to prior devices and only a very small percent of all new 
device submissions must undergo rigorous review and a randomized trial may still 
not be mandated by FDA for devices (Wright 2002; Devo 2004).
In the majority of instances “a device need only do technically what it claims and be 
reasonably safe” for approval to occur (Devo 2004). Wright highlights three areas where 
there are key differences in the product development process of devices versus drugs: the 
process of concept discovery, device classiﬁ  cation, and iterative development (Wright 
2002). Drugs are typically identiﬁ  ed in a massive trial and error screening process with a 
deﬁ  ned clinical trial program whereas devices are designed to a particular speciﬁ  cation 
and regulation is geared to safety of the design and manufacturing process. The iterative 
nature of the approval process is manifested when new devices are approved with the 
argument that the design or indication is merely an improvement or modiﬁ  cation of an 
older technology or indication. Even when clinical trials are initiated for high-risk devices 
(such as the ones to be discussed below), the clinical trial data is focused on design safety 
and performance as opposed to clinical efﬁ  cacy and rationale for the devices and random-
ized trials are very infrequently performed. As Furlan and Fisher point out, the end result 
is an approval process based on a mechanistic endpoint versus the “tougher” endpoint of 
clinical efﬁ  cacy (Furlan and Fisher 2005). Thereafter, interventionalists are unlikely to 
enroll patients in clinical trials of devices versus medical controls when these interven-
tionalists have a strong treatment (and possibly ﬁ  nancial) imperative toward procedures. Therapeutics and Clinical Risk Management 2008:4(1) 20
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In the ﬁ  eld of cerebrovascular disease, the differing standards 
for devices versus drug therapy was most recently highlighted 
with the approval of the Merci catheter for ‘clot removal’ in 
patients with stroke but the problem is also apparent in the use 
of other devices for stroke treatment and prevention (Becker 
and Brott 2005). Medical devices for the treatment of cerebro-
vascular disease are becoming rampant. Forecasts suggests 
almost quadruple growth in mechanical cerebral embolectomy 
over the next 10 years, a potential for up to 100,000 stroke 
patients potentially eligible for PFO closure and a future explo-
sive growth for carotid stenting that is already manifested by 
increasing numbers of cardiologists and other interventionalists 
performing these procedures in both academic and community 
hospital settings (Sg2 Intelligence Reports 2006).
While these interventions have the potential to revolutionize 
our approach to cerebrovascular disease, the paradox is that this 
explosive growth in procedural interventions is not supported 
by the clinical trial data at this time. This review focuses on 
the lack of data to support widespread use of endovascular 
procedures in four areas of cerebrovascular disease and 
emphasizes the need for rigorous clinical trials to be completed 
prior to routine adoption of interventions for stroke.
Percutaneous closure of patent 
foramen ovale for prevention 
of recurrent stroke
Patent foramen ovale (PFO) is represented as the most frequent 
potential source of cardiac embolism in patients  60–65 years 
of age with no other obvious etiology for the stroke despite an 
extensive diagnostic evaluation (‘cryptogenic stroke’) (Horton 
and Bunch 2004; Wu et al 2004; Kizer and Deveruex 2005). 
Estimates are that 1/4 of all adults have a persistent PFO. 
The prevalence of PFO in cryptogenic stroke is particularly 
common but the relationship of a PFO to ischemic stroke is 
based mainly on associations seen in various case-control 
studies. In a meta-analysis of the risk of stroke related to PFO, 
the odds ratio was 5.01 (95% CI 3.24–7.75) among patients 
55 or younger. There was no association of PFO and stroke 
among older persons with a reported odds ratio of 1.20 (95% 
CI 0.56–2.56). However, while anecdotal observation of clot 
passing from the right to left atrium is well-known, a causal 
etiology such as venous thrombosis with subsequent right-to-
left cardiac shunt is rarely identiﬁ  ed. Overall, the yearly risk 
of cryptogenic stroke in healthy persons with PFO has been 
estimated to be around 0.l percent. However, once a PFO 
(with or without ASA) is identiﬁ  ed in a younger patient with 
stroke, one must consider other causes of stroke including 
hypercoaguable and autoimmune states, occult arrhythmias, 
and any other anomalies of the cervico-cerebral vessels before 
attributing the stroke mechanism to a PFO. It is telling that 
neurological events recur in as may as twenty percent of 
patients who undergo surgical closure suggesting that alternate 
mechanisms may play a role in patients with presumed PFO-
related strokes (Maisel and Laskey 2005).
The management for preventing recurrent stroke in 
patients with cerebral ischemia attributed to a PFO includes 
anti-platelet drugs, anticoagulants and surgical or transcath-
eter closure. There are no randomized trials of anti-platelet 
versus anticoagulant therapy and no completed randomized 
trials of percutaneous PFO closure (Flachskampf and Daniel 
2005; Maisel 2005). While many have advocated warfarin 
therapy as the preferred medical intervention for comparison 
with percutaneous closure, there is only limited data support-
ing the preferential use of warfarin for PFO related-stroke.
The largest observational study of medical therapy for PFO 
related stroke is the Patent Foramen Ovale in Cryptogenic 
Stroke Study (PICSS), a sub-study of the Warfarin-Aspirin 
Recurrent Stroke Study (WARSS) (Homma et al 2002; Mohr 
et al 2001). In that study, of 630 patients who underwent TEE, 
there were only 98 patients with cryptogenic stroke and patent 
foramen ovale and only limited conclusions as to the relative 
beneﬁ  t of anticoagulation could be made. In the PICSS cohort, 
there was a trend toward a beneﬁ  t for warfarin compared to 
aspirin. However, this beneﬁ  t was not speciﬁ  c to the PFO-
related strokes but applied to all cryptogenic stroke patients 
in PICSS with or without PFO. Additionally, the cryptogenic 
stroke patients in PICSS were poorly characterized and the 
cohort was comprised of predominantly older stroke patients. 
In two subsequent smaller observational studies of approxi-
mately 50 patients with PFO associated stroke there was a trend 
to a beneﬁ  t for warfarin but both of these studies were limited 
by a lack of random assignment of drug therapy (Cujec et al 
1999; Schneck et al 2002). As such, current guidelines of the 
American Academy of Neurology guidelines regarding the 
management of PF-related stroke state that there is insufﬁ  cient 
evidence at this time to support the use of warfarin preferen-
tially as compared with aspirin (Messe et al 2004). Regardless 
of therapy used, the recurrence rate for PFO related stroke is 
fewer than 3 percent in several studies. Only one study reported 
a recurrence rate that was substantially higher and that was 
in the context of those patients with a combination of a PFO 
and ASA where the recurrence rate was 15.2% despite aspirin 
therapy (Mas et al 2001). This ﬁ  nding has not been conﬁ  rmed 
in other observational studies however, and even in this study, 
the rate of PFO related stroke without ASA was less than 
1 percent per year which would argue against warfarin use.Therapeutics and Clinical Risk Management 2008:4(1) 21
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The recent introduction of percutaneous devices for closure 
of a PFO has led to widespread adoption of this approach, in 
place of medical therapy alone, for those patients at risk of 
recurrent stroke. The justiﬁ  cation to support closure being 
superior to medical therapy is based on a meta-analysis of 
surgery versus anti-platelet therapy with an odds ratio of 
0.36 but wide conﬁ  dence intervals of 0.04 to 3.09. Certainly 
transcatheter closure seems to be an attractive option to patients, 
particularly as compared with surgery, since percutaneous 
closure has been touted as a ‘permanent ﬁ  x’ that would obviate 
the need for anticoagulation though not concurrent anti-platelet 
therapy. In retrospective series, the one-year rates of recurrent 
cerebral ischemic events ranged from 0%–4.9% for closure 
and 3.8%–12% for medical therapy but complications of 
device implantation have been reported in upwards of 10% of 
patients (Maisel and Laskey 2005). Two devices, the Amplatzer 
PFO Occluder and the Cardioseal Septal Occlusion System 
are available in the United States but only on a Humanitarian 
Device Exemption (HDE) that limits closure to those patients 
who have had a recurrent cryptogenic stroke who have failed 
conventional drug therapy deﬁ  ned as oral anticoagulation with 
a therapeutic international normalized ratio (INR) (Flachskampf 
and Daniel 2005; Kizer and Deveruex 2005; Maisel and Laskey 
2005). Otherwise, PFO closure is being done on an off-label 
basis as there is no data that clearly shows superiority of closure 
over medical therapy. Despite this lack of data supporting 
PFO closure, randomized studies to investigate medical 
therapy versus transcatheter PFO closure (such as CLOSURE, 
RESPECT, and the Cardia Star trials) have experienced very 
slow enrollment rates as off label use of devices has become 
rampant. The ready availability of PFO devices, however, 
cannot justify empiricism in the absence of clinical science 
(Flachskampf and Daniel 2005; Maisel and Laskey 2005). 
The Stroke Council of the American Heart Association and 
the American Academy of Neurology have issued guidelines 
that suggest patients with cryptogenic stroke and PFO should 
only undergo PFO closure in the context of randomized clinical 
trials; otherwise, medical therapy should be the preferred option 
at this time for patients with ﬁ  rst-ever cryptogenic stroke and 
PFO (Messe et al 2004; Maisel and Laskey 2005).
Stenting for extracranial 
atherosclerotic carotid artery disease
Carotid endarterectomy for extracranial asymptomatic and 
symptomatic stenosis is a well established treatment option 
(Chaturvedi et al 2005). Large, prospective, randomized 
North American and European trials have conﬁ  rmed the 
efﬁ  cacy of carotid endarterectomy for patients with a prior 
history of stroke or TIA (symptomatic carotid stenosis) 
attributable to ipsilateral moderate to severe extra cranial 
carotid atherosclerosis who met otherwise well-deﬁ  ned study 
criteria (North American Symptomatic Carotid Endarterec-
tomy Trial Collaborators 1991; ECST Investigators 1998; 
Ferguson et al 1999; Chaturvedi et al 2005). Similar results 
have been reported from European and North American ran-
domized trials of highly selected patients with carotid stenosis 
and no prior history of cerebrovascular disease (Executive 
Committee for the Asymptomatic Carotid Atherosclerosis 
Study 1995; Halliday et al 2004; Chaturvedi et al 2005).
American Academy of Neurology guidelines for carotid 
endarterectomy (CEA) were based on these well-designed 
randomized trials that demonstrated CEA is beneﬁ  cial for 
stroke risk reduction, as compared with medical therapy, for 
patients with moderate to severe carotid stenosis (Chaturvedi 
et al 2005). The recommendations speciﬁ  cally state that 
the peri-operative stroke/death rate should be less than 
6 percent for symptomatic disease and less than 3 percent 
for asymptomatic disease. Patients with high grade stenosis 
and recent TIA or minor stroke should undergo CEA within 
two weeks of the event. The guidelines also state that 
patients being considered for CEA should haven at least 
5 year life expectancy. Furthermore, the data regarding 
CEA for asymptomatic disease is proven only for patients 
40–75 years with very well-deﬁ  ned clinical characteristics 
and women with either asymptomatic or moderate (50–69 
percent) symptomatic derive a less clear beneﬁ  ts from CEA 
as opposed to men. A key point of the guidelines is that 
whereas CEA can provide a reasonable reduction in stroke 
risk, careful patient selection and well-deﬁ  ned diagnostic 
and surgical parameters are paramount. The advent and 
widespread use of angioplasty and stenting technology in 
coronary arteries has been extended to the extra cranial 
carotid, vertebral and intracranial arteries with tremendous 
enthusiasm and hype. .Carotid artery stenting (CAS) is now 
being adopted as a less-invasive and presumably equally 
effective treatment for to CEA for the management of 
carotid stenosis. Carotid angioplasty and stenting (CAS) 
may obviate the need for surgery and advocates argue that 
this approach is associated with fewer strokes, cardiac events 
and other complications particularly including postoperative 
hematoma and cranial nerve injury. However, whereas, the 
clinical efﬁ  cacy of carotid endarterectomy as compared 
with medical therapy has been well established based on 
well-designed randomized clinical trials only recently 
has there been evidence suggesting CAS is a reasonable 
alternative to CEA outside of observational studies.Therapeutics and Clinical Risk Management 2008:4(1) 22
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Case selection is clearly paramount regardless whether 
CAS or CEA is the procedure of choice. CEA trials revealed a 
beneﬁ  t/risk ratio for patients with asymptomatic or moderate 
grade symptomatic stenosis that was much smaller compared 
to the beneﬁ  t/risk for patient with high grade carotid artery 
stenosis patients (Chaturvedi 2003; Chaturvedi et al 2005). 
The current consensus for a minimal standard for CEA is 
a major complication rate of less than 3 percent (stroke, 
MI, and death) derived from the asymptomatic trial data 
(Lanska and Kryscio 1997). Furthermore, in the CEA trials, 
the comparison was made of medical therapy versus surgery 
with angiographic conﬁ  rmation of lesions along with follow-
up by neurologists with expertise in stroke presumably 
providing independent veriﬁ  cation of stroke event rates. 
However, while the reliance on non-invasive imaging to 
assess degree of stenosis is problematic as regards to accuracy 
of stenosis current surgical practice is to eliminate the 
use of preoperative angiography for estimation of the degree 
of stenosis because, in the ACAS study, a full 1 percent of 
complications in the surgical arm were directly related to 
angiography (Executive Committee for the Asymptomatic 
Carotid Atherosclerosis Study 1995; Johnston and Goldstein 
2001). With this approach, surgeons have been reporting 
30 day complication rates of 2 percent or less in their current 
series for CEA and this is the benchmark which CAS must 
achieve in randomized studies with CEA (LaMuraliga et al 
2004).
A meta-analysis of the ﬁ  ve available randomized trials, 
totaling 1154 patients (577 patients in each arm), showed 
that the composite endpoint for CAS versus CEA was not 
different at the one month stroke/death endpoint (Qureshi 
et al 2005). The one month stroke rate and disabling stroke 
rate was also similar. The major difference was that the one 
month MI rate in the 814 total patients for whom data was 
available was lower for CAS (RR 0.03; 95% CI 0.1–0.9) 
and the cranial nerve injury rate for CAS was also lower in 
the 918 analyzed patients (RR 0.05; 95% CI 0.01–0.3). At 
one year, no signiﬁ  cant differences in the rate of ipsilateral 
stroke was observed in the 814 patients analyzed (RR 0.8; 
95% CI 0.5–1.2) (Qureshi 2005). In the included series, how-
ever, four of the ﬁ  ve studies were restricted to symptomatic 
carotid disease. The results from SAPPHIRE, the most recent 
trial, are in conﬂ  ict with the other early trials where there 
were worse outcomes for CAS. Whether experience of the 
interventionalists with the early devices or different patient 
populations explains the dichotomy is somewhat less clear. 
Major criticism of two early studies focused on both sample 
size inadequacies and procedural/recruitment difﬁ  culties 
(Alberts et al 1997; Naylor et al 1998). In the CAVATAS 
study, signiﬁ  cant carotid artery restenosis ( 70%) was also 
greater for CAS versus CEA (18.5% versus 5.2%, p = 0.0001) 
(Dominick et al 2005). However, it should be recognized that 
most of the endovascular procedures in CAVATAS were 
angioplasties without stenting. A subsequent meta-analysis 
of 34 studies noted cumulative restenosis rates after 1 and 
2 years of 6% and 7.5% in those studies, using a lower 
restenosis threshold of 50%–70% and 4% in the ﬁ  rst 2 years 
after CAS for a restenosis threshold of 70%–80% (Gröschel 
et al 2005). These authors noted that the early restenosis 
rates after CAS compare well with those reported for CEA. 
However, this analysis of the peer-reviewed literature also 
indicates that the early restenosis rates after CAS might be 
higher than previously suggested in observational surveys 
(Gröschel et al 2005).
Thus, up until, the SAPPHIRE study, there was little data 
to support preferential use of CAS versus CEA. As opposed 
to the other randomized studies, SAPPHIRE was a study 
of CAS (with deployment of a distal protection device to 
minimize emboli from the site of the plaque) as compared to 
CEA for patients otherwise deﬁ  ned as high risk for surgery 
(Yadav et al 2004). SAPPHIRE was a study of 747 patients 
of which 413 patients were treated as part of a registry (406 
were treated by CAS and 7 underwent CEA). 334 cases were 
randomized to either CEA or CAS of which 310 were treated; 
there were 159 casers in the CAS arm and 151 cases in the 
CEA arm. The inclusion criteria included a deﬁ  nition of the 
high risk patient: congestive heart failure, positive stress 
test, need for cardiac surgery, severe pulmonary disease, 
contralateral carotid occlusion, contralateral laryngeal nerve 
palsy, recurrent carotid stenosis from prior CEA, age  80 
years, previous radical neck surgery or radiation therapy 
to the neck. Symptomatic patients were enrolled with  50 
percent stenosis and asymptomatic patients were enrolled 
with  80 percent stenosis. The CAS procedural success 
rate was 91.2%.
The 30 day event rate showed a signiﬁ  cant difference 
between CAS and CEA of 5.8 percent for the combined end-
point of stroke, MI, or death versus 12.6 p   0.047 but these 
results were driven by non-Q-wave myocardial infarctions 
(MI). One goal of the study was to demonstrate equivalence 
of CAS and CEA and this was achieved by the study. Further-
more, while the differences were not statistically signiﬁ  cant 
(p = 0.17), the trend favored a better outcome for CAS for 
the combined endpoint. The intention to treat analysis thirty 
day outcomes included a death rate of 1.2%, stroke rate of 
3.6% and MI rate of 2.4% (all non-q wave MI) for the CAS Therapeutics and Clinical Risk Management 2008:4(1) 23
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and a death rate of 2.5%, stroke rate of 3.1% and MI rate of 
6.1% (1.2% q-wave MI) for the CEA arm. The combined 
endpoint of stroke, death and/or MI was 4.8% for CAS and 
9.8% for CEA. The major ipsilateral stroke rate was 0.6% 
for CAS and 1.2% for CEA whereas the minor ipsilateral rate 
was 2.4% for CAS and 0.6% for CEA. The one year analysis 
was also reported. At one year, the outcomes included a death 
rate of 7.4%, stroke rate of 6.3% and combined endpoint of 
stroke, death and 30 day MI rate of 12.2% for the CAS arm 
and a death rate of 13.5%, stroke rate of 7.9% and combined 
endpoint of stroke, death at one-year and/or 30 day MI rate 
of 20.1% for the CEA arm with a p-value for the combined 
endpoint of 0.05 favoring CAS. While major stroke was 
less common for CAS in the randomized arm (0.6%) versus 
surgery (3.0%), major ipsilateral stroke was as common in 
the CAS registry (3.2%) as compared with CEA and minor 
stroke was less common for CEA (1.8%) as opposed to 
CAS in either the randomized CAS (3.6%) or registry CAS 
arms (3.9%).
Subsequent claims have been made that CAS has now 
been established as the treatment of choice for high risk 
individuals and other patients (Roubin et al 2006). Recently, 
an FDA advisory recommended approval of CAS along with 
a distal protection system for patients with symptomatic 
carotid artery stenosis who are otherwise at high surgical risk 
This approval was based on data from the SAPPHIRE study 
(Yadav et al 2004). However, the data from the SAPPHIRE 
study and other single-arm studies, while favorable to CAS 
versus CEA raise many questions about generalizability 
such that the widespread adoption of CAS for management 
of both symptomatic and asymptomatic disease should be 
approached with caution.
When the analysis of SAPPHIRE data was presented by 
asymptomatic versus symptomatic carotid artery disease, 
the cumulative incidence of the combined primary endpoint 
was 16.8 percent for those who underwent CAS versus 16.5 
percent for those who underwent CEA though the results at 
30 days for the symptomatic patients and at one year were 
2.1 vs 9.3 (p = 0.18) and 16.5 versus 16.8 CAS (p = 0.5). 
The data were driven by the MI population. For patients with 
asymptomatic carotid artery stenosis, the rate was 9.9% for 
those who received a stent and 21.5% for those who under-
went CEA and the 30 day combined stroke/death and/or MI 
rate for the asymptomatic patients who underwent CAS was 
5.4% versus 10.2% for CEA (p = 0.20).
A number of issues need to be considered as we analyze 
CAS versus CEA in the SAPPHIRE trial. For one thing, 
there is no medical arm in this and other stent studies. This is 
important as the nature of medical therapy for the treatment 
of carotid artery disease has changed over time with more 
aggressive anti-platelet therapy, more widespread use of 
statins and more aggressive blood pressure control. In the 
past decade since the completion of the various CEA trials, 
best medical therapy has gotten better. To therefore state 
that medical therapy was not believed to be suitable for the 
patients enrolled into SAPPHIRE based on preferences of 
the referring physicians or the SAPPHIRE investigators 
is disingenuous. The trial is also biased to asymptomatic 
disease with 70 percent of the cases being asymptomatic; 
SAPPHIRE included 96 symptomatic and 219 asymptomatic 
patients though there was relative balance between the CAS 
and CEA groups regarding symptomatic versus asymptom-
atic disease. (Alberts et al 1997). Additionally 30 percent of 
the cases were redo procedures for which the management 
is different than de novo carotid atherosclerotic disease. 
Finally, of 747 cases, only 334 were randomized whereas 
of the 413 registry patients, 306 underwent CAS and 7 had 
CEA. The SAPPHIRE conclusion for the worse outcome 
rates in both the CAS and CEA arms as compared with the 
older randomized CEA studies is that the SAPPHIRE is 
different from the previous CEA trials in that these patients 
were higher risk patients. Based on the worse outcomes, 
seen in even the CAS arms, a logical rejoinder is that high-
risk patients should be left alone and treated medically and 
the current stroke guidelines do not support routine use 
of CAS pending more deﬁ  nitive data (Sacco et al 2006). 
This is particular critical to the assessment of patients with 
asymptomatic carotid artery stenosis. While one could argue 
that the beneﬁ  t outweighs the risk for symptomatic patients 
for whom the cross-over point for beneﬁ  t from CEA (and 
perhaps by extension CAS) occurs at around 3 months, the 
beneﬁ  t for CEA for asymptomatic disease is not achieved 
till close to one year and a statistically signiﬁ  cant was not 
seen till after two and one-half years. While the asymptom-
atic CEA randomized trials may have been “robust”, those 
results do not translate over to the SAPPHIRE population 
(Yadav et al 2005). Chaturvedi and colleagues have further 
argued that more aggressive use of statin therapy and other 
modalities for stroke risk reduction may reduce the absolute 
beneﬁ  t for any revascularization procedures (Chaturvedi 
2003; Betancourt et al 2004). It is worth noting here that 
while registry data presents an even rosier picture of CAS, 
the argument for CAS remains unsupported as compared 
with CEA from the randomized studies or medical therapy. 
The most recent registry, CAPTURE, sought to determine 
whether CAS can be performed safely by physicians with Therapeutics and Clinical Risk Management 2008:4(1) 24
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varying levels of experience who underwent a Guidant, Inc. 
mandated training program; only 1/3 of cases could come 
from hospitals with high levels of CAS experience (Gray 
et al 2006). 2500 patients were enrolled in this post-mar-
keting study of which 23.8 percent were above the age of 
80 and only 9.3 percent had symptomatic carotid stenosis. 
In CAPTURE, the rate of stroke or death was 5.1 percent 
and the rate of stroke, death and MI was 5.7 percent. For 
asymptomatic patients the rate was 4.4% and 4.9% respec-
tively. For the symptomatic patients the stroke and death 
rate was 12 percent and the stroke/death/MI rate at 30 days 
was 14.2 percent.
By comparison, in a CEA registry, Mozes et al (2004) 
reported the Mayo Clinic experience from 1998 to 2002 
in light of the SAPHHIRE data with high versus low risk 
CEA. Of 776 CEAs, 42 percent were considered high risk 
by SAPPHIRE criteria. The overall stroke risk in the Mayo 
Clinic series was 1.4% (2.9% symptomatic and 0.9% in 
the asymptomatic patients and the overall mortality was 
0.3 percent (symptomatic 0% and asymptomatic 0.2%. The 
only difference was that non-Q wave MI was more frequent 
in the high-risk group (3.1 versus 0.9 p   0.05) and the 
composite endpoint was more frequent in the symptomatic 
(9.3 versus 1.6% p   0.005) but not the asymptomatic 
high risk groups. A critique of this paper by Ouriel (2004) 
argued that any comparisons of high risk versus low risk 
surgical patients was irrelevant and that the only validity 
was a randomized trial of high-risk CEA versus CAS. This 
argument is appropriate and only by direct comparison 
between the two modalities can allow us to understand 
the best procedural option. It is still telling however, that 
the overall event rate for stroke and death was lower in the 
Mayo Clinic experience as compared to the SAPPHIRE 
trial data, raising questions about the generalizability of the 
SAPPHIRE data (Ouriel 2004).
As an aside, age is a particularly important factor. While 
patients in the older NASCET CEA subgroup (age 75–80) 
seemed to have a greater risk stroke reduction following 
surgery as compared to medical therapy, the lead-in phase 
component of the CREST study and the CAPTURE registry 
noted that age greater than 80 was an independent risk fac-
tor for a worse 30 day stroke or death rate. For CREST the 
rate was 5.3% for patients age 70–79 and 12.1 percent in 
CREST for patients  age 80. In CAPTURE, octogenarians 
also fared less well with a combined endpoint at 30 days of 
8.2 for those above age 80 and 4.9 percent below the age of 
80. For stroke, the rate was 6.6% for those above age 80 and 
3.5% below the age of 80.
Recently, the SPACE and EVA-3S 30 day results became 
available. SPACE was a non-inferiority trial of 1200 German, 
Swiss and Austrian patients with retinal or hemispheric TIA 
or ischemic stroke and ipsilateral carotid stenosis greater than 
70% by ultrasound (corresponding to  50% by NASCET 
and  70% by ECST criteria) (SPACE Collaborative Group 
2006). The patients were randomized to either CEA or CAS 
with a primary endpoint of ipsilateral ischemic stroke or death 
from randomization up to 30 days post-procedure. Surgeons 
and interventionalists in SPACE were required to have at 
least 25 successful procedures to participate in the study. 
EVA-3S was a French study of symptomatic patients with 
symptomatic carotid artery stenosis of  60% by NASCET 
criteria that was stopped prematurely after enrollment of 
527 patients (Mas et al 2006). One critical difference between 
SPACE and EVA-3S was that the interventional physician 
had to perform fewer CAS (12) to be a study participant as 
opposed to the surgeons (25 CEAs) in EVA-3S. By contrast 
to SAPPHIRE, non-atherosclerotic carotid artery disease and 
patients with recurrent stenosis were excluded in both SPACE 
and EVA-3S. Furthermore, in SPACE, embolic protection 
devices were optional and EVA-3S did not employ emboli 
protection devices in the initial phase of the study. Addition-
ally myocardial ischemia was not a speciﬁ  ed endpoint for 
the SPACE study.
In the SPACE study, the stroke/death rate was 6.84% 
for CAS and 6.34% for CEA. Other than death at 30 days 
(4 in the CAS arm and 5 in the CEA arm) and intracerebral 
hemorrhage (1 in the CAS arm and 5 in the CEA arm), there 
was a trend to better outcomes for the CEA group in all other 
parameters including procedural failure, ipsilateral stroke, 
any stroke, and disabling stroke. As seen in previous studies, 
the risk of complications in SPACE was higher for women 
and older patients. The EVA-3S study was actually stopped 
early because of an excess of stroke or death in the CAS arm 
(9.6%) versus the cEA arm (3.9%) with a relative risk of 2.5 
(95% CI 1.2–5.1); there no signiﬁ  cant difference in the 30-day 
incidence rates of myocardial infarction. There were more 
systemic complications (mainly pulmonary) after CEA and 
more local complications after CAS but the differences were 
not signiﬁ  cant. As in SAPPHIRE, cranial nerve injury was 
more common after CEA compared with CAS (7.7% versus 
1.1%; p   0.001)As the stroke rates were noted to be high in 
the initial phase of EVA-3S, emboli protection devices were 
then employed in this study and yet the incidence of stroke 
was still higher for CAS (7.9%) as compared with CEA. 
As, the results did not meet the prespeciﬁ  ed non-inferiority 
margin for CAS, the conclusion of the SPACE investigators Therapeutics and Clinical Risk Management 2008:4(1) 25
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was that, widespread use of CAS is not justiﬁ  ed, at least 
based on the initial short-term 30 day results. The EVA-3S 
investigators further noted the low rates of CEA in their study 
may reﬂ  ect a decrease in risk of surgery since the earlier 
surgical trials reﬂ  ecting improved surgical technique and 
perioperative management over time.
These recent trials therefore set the bar much higher for 
those who would advocate widespread adoption of CAS 
for carotid artery disease. While the United States Center for 
Medicare and Medicaid Services (CMMS) reimburses treat-
ment for patients at high risk for carotid endarterectomy who 
have symptomatic carotid stenosis, who are participants in an 
investigational device (IDE) study, or are participants in an 
FDA mandated post-approval study such as the CAPTURE 
study, we should therefore be ultra-cautious to in our case 
selection of patients for CAS until completion of further 
randomized studies. Signiﬁ  cantly, the pace of enrollment in 
SAPPHIRE slowed in early 2002 because of several non-
randomized carotid stenosis registries that began around 
that time and so SAPPHIRE was therefore terminated early 
because of slow enrollment of patients. Whenever possible, 
physicians should preferentially refer patients for random-
ized comparison studies rather than falling prey to a stenting 
imperative. There remain a number of available options 
worldwide. CREST (Carotid Revascularization Endarterec-
tomy versus Stent) is a randomized trial of CEA and CAS 
for nominally low surgical risk patients. Initially the trial 
was designed for symptomatic patients with  50 percent 
carotid stenosis only nut has recently included to expanded 
to include asymptomatic patients with  60 carotid artery 
stenosis (70% by ultrasound) as well. While enrollment had 
lagged in this study, gradually randomization is increasing 
and as of 2005, 600 persons had been enrolled in the study. 
A follow-up study to CAVATAS is also underway, the 
International Carotid Stenting Study (ICSS) with 600 patients 
accrued to date.
Intracranial stenting
Stenting of the intracranial circulation, by comparison with 
CAS, is still very much in its infancy. The frequency of 
intracranial stenosis related ischemic stroke may be as large 
as the frequency of stroke attributable to extracranial large 
vessel atherosclerotic disease (Chimowitz et al 1995; Sacco 
et al 1995; Wityk et al 1996). Randomized clinical trial 
data, from the WASID investigators, of medical therapy for 
symptomatic intracranial atherosclerosis patients followed 
for an average of 1.8 years, showed that aspirin (1300 mg 
daily) has fewer adverse events and equal beneﬁ  t to warfarin 
(INR 2–3) (Chimowitz et al 2005). In this population, the 
primary endpoint of ischemic or hemorrhage stroke or 
vascular death occurred in 22 percent of patients in either 
group. However, the rate of death, major hemorrhage and 
myocardial infarction or sudden death was higher in the war-
farin group. As a pre-speciﬁ  ed secondary endpoint, the rate 
of ischemic stroke in the territory of the stenotic artery was 
15 percent for the aspirin treated patients and 12.1 percent 
for the warfarin treated group but this was not a statistically 
signiﬁ  cant observation. Therefore, in light of the high stroke 
and complication rates for those patients treated medically 
(ie, WASID); there has been an understandable groundswell 
of interest in intracranial stenting. However, this procedure is 
associated with great risk and variable restenosis rates have 
been reported with limited long term follow-up of patients; 
complication rates range from 9%–38% post-stent have been 
reported (Jiang et al 2004; Abou-Chebl et al 2005; Kessler 
et al 2005; Lee et al 2005; Lylyk et al 2005; Qureshi et al 
2005; Strabue et al 2005). One author has observed that 
“stent-assisted intracranial procedures are becoming a routine 
clinical practice” despite the limited evidence to support 
that conclusion (Kessler et al 2005). To date, there are only 
two, non-randomized multicenter feasibility trials of small 
numbers of patients (Higashida et al 2005).
In the SSYLVIA study restenosis occurred in at least 
1/3 of all patients with close to 39.1 percent of the recurrent 
stenoses being symptomatic (SSYLVIA investigators 2004). 
SSYLIVA study employed the NEUROLINK device in 
61 patients with intracranial or extra-cranial vertebral steno-
sis. Restenosis occurred in 12/37 (32.4%) of intracranial cases 
and 6/14 (42%) of extra-cranial vertebral stenosis. Strokes 
occurred in 4/55 (7.3%) of patients beyond 30 days. In a 
report of the multicenter experience with the WINGSPAN 
self-expanding system, 45 patients were described who 
underwent WINGSPAN device placement for recur-
rent symptoms despite medical therapy (Higashida et al 
2005; Hartmann 2006). The average pre-stent stenosis 
was 72 percent and immediately after stent placement, the 
degree of stenosis was 52 percent with the stroke/death rate 
reported as 4.4% within 30 days and 7.1% at six months. 
Both of these devices have subsequently been approved in the 
United States under an FDA Humanitarian Device Exemp-
tion (HDE) and an interventional society position paper has 
declared that this procedure should be offered to patients 
who “fail medical therapy” with third party reimbursement 
(Higashida et al 2005).
Otherwise, the role of both coated and uncoated stents in 
the intracranial circulation is poorly deﬁ  ned and only case Therapeutics and Clinical Risk Management 2008:4(1) 26
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series exist at this time with variable reports of morbidity, 
mortality and restenosis (Abou-Chebl and Yadav 2005; 
Boulos et al 2005). While, deployment of drug eluting 
stents has been proposed as one solution to the high rate 
of intracranial restenosis, by analogy to coronary artery 
disease, this concept should also be called into question in 
light of recent questions about the strength of the evidence 
for these stents in the management of coronary restenosis 
(Tung et al 2006). Chatervedi and Caplan emphasize that, 
given the lack of randomized studies, variable reported short 
and long-term complication rates, limited neurological fol-
low-up, and an absence of randomized clinical trial data, 
intracranial stenting is a procedure that must be reserved 
only or those patients with symptomatic intracranial ath-
erosclerotic vascular disease who have had recurrent events 
despite aggressive maximalmedical therapy who have a 
presumed annual stroke rate  10%–15% (Chaturvedi and 
Caplan 2003). These patients should also be treated with 
under formal investigation review board (IRB) oversight 
and continued long-term vascular neurology follow-up for 
assessment of complications and recurrent events should 
be mandatory (Benesch and Chimowitz 2000; Chaturvedi 
and Caplan 2003).
Mechanical thromboembolectomy 
for acute ischemic stroke
At present, intravenous tPA is the only FDA approved 
therapy for acute ischemic stroke. However, this therapy 
can only be administered to those patients treated within 
three hours of acute symptom onset and the treatment is 
also limited to patients at low risk of systemic hemorrhagic 
complications such that patients on anticoagulants or who 
have undergone recent surgical procedures are ineligible for 
tPA. Furthermore, the beneﬁ  t of intravenous tPA is thought 
to be less effective for patients with large strokes typically 
the result of large proximal cervico-cerebral arterial occlu-
sions (Kasner 2004; Ng et al 2004). Intra-arterial mechanical 
and/or pharmacologic thrombolysis has been adopted as an 
alternate strategy for appropriate patients either as a substi-
tute or in addition to intravenous TPA. The rationale for this 
approach is based on the seminal PROACT studies (Furlan 
et al 1999; Kasner 2004).
PROACT II was a double-blind randomized trial of 
intra-arterial pro-urokinase of 180 patients with proximal 
middle cerebral artery occlusion who were randomized to 
IA pro-urokinase plus heparin versus heparin alone (Furlan 
et al 1999). In the study, there was a recanalization rate of 
66% with the study drug and only 18 percent for the control 
group (p   0.001). Forty percent of the pro-urokinase treated 
patients but only 25 percent of control patients had a good 
outcome deﬁ  ned as modiﬁ  ed Rankin score of less than or 
equal to 2. The intracranial hemorrhage rate was 10% for 
the pro-urokinase arm and 2% for the control arm. Because 
of the study size and lack of a robust ﬁ  nding for the primary 
outcome, the FDA did not approved IA pro-urokinase for 
acute ischemic stroke.
However, the PROACT studies served as a proof of 
concept for intra-arterial thrombolysis and many centers 
have utilized this therapy on an unapproved off-label basis 
while clinical trials using combinations of intravenous and 
intra-arterial TPA for acute stroke are currently underway 
(Broderick 2004; Kasner 2004). The argument has been that 
IV TPA does not open larger vessels such as the internal 
carotid artery or the proximal middle cerebral artery as well 
as more distal arterial occlusive lesions (ASITN et al 2001; 
Ng et al 2004). Furthermore, patients with large strokes 
(NIHSS   20) have a much lower chance of improving to 
NIHSS 0 or 1. Fifty two percent of patients with NIHSS 
  10 had little or no deﬁ  cit as compared to 8% of patients 
with NIHSS   20 in the NINDS tPA studies (ASITN et al 
2001; Ng et al 2004). An interventional society position 
statement thereby suggested that IA thrombolysis was 
appropriate in selected patients despite lack of randomized 
data and that criteria such as the location of the arterial 
occlusive lesion, magnitude of the neurologic deﬁ  cit and 
time to treatment were potential criteria that might deter-
mine which patients should go directly for intra-arterial 
thrombolysis in place of FDA-approved intravenous TPA 
for acute stroke (ASITN et al 2001). Anecdotal evidence 
suggests that this approach is being widely adopted nation-
wide in both academic and community medical centers. 
Caution about this assumption is however warranted. A 
meta-analysis of IA thrombolysis (344 cases) versus IV 
thrombolysis (76 cases)for basilar artery occlusion, for 
which the assumption has been that IA thrombolysis is the 
preferred modality, did show that recanalization was more 
common with IA versus IV thrombolysis (Lindsbert and 
Mattle 2006). But death and dependency was equal for both 
IA and IV thrombolysis. Thus, while centers with experi-
enced interventionalists might still opt for IA thrombolysis 
for basilar ischemia, intravenous thrombolysis is still a very 
reasonable alternative particularly in those centers where 
an interventionalist is not readily available.
Recently the MERCI retriever was approved through the 
510 K process. Becker and Brott reviewed the 510 K approval 
process used for this device that based on the predicate device Therapeutics and Clinical Risk Management 2008:4(1) 27
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of the Concentric retriever, approved in May 2001 for “use 
in the retrieval of foreign bodies in the peripheral coronary 
and neuro-vasculature” (Becker and Brott 2005). The advan-
tages of the catheter based on the MERCI trial (Mechanical 
Embolus Removal in Cerebral Ischemia) patient selection 
criteria included extension of the window of opportunity to 
8 hours for treatment of intracranial vertebral, basilar, intracra-
nial ICA or M1 division MCA occlusions; patients with INR 
up to 3.0 or platelet count less than 30,000/uL could be treated 
as well. The MERCI trial presented to the FDA was a single 
arm prospective non-randomized trial of patients treated 
within 8 hours of symptom onset (Smith et al 2005). The 
primary endpoint was revascularization of the target vessel 
with a low rate of serious adverse events (vessel perforation, 
vascular dissection and distal clot embolization). The MERCI 
investigators compared their data to the placebo control arm 
of PROACT II. As described above, the PROACT-II was 
a study limited to proximal MCA occlusions whereas the 
intracranial vessels involved in the MERCI trial were more 
heterogeneous. 141 patients were treated (151 in the intention 
to treat analysis) using the MERCI retriever with a recanali-
zation rate of 68/141 compared to the historical PROACT-II 
placebo control rate of 18 percent recanalization. A clinically 
signiﬁ  cant device event-related complication rate of 10/147 
(7%) was reported in the MERCI trial and the symptomatic 
intracranial hemorrhages rate was reported as 11/141 (7.8%). 
Clinical neurological outcome was only a secondary endpoint 
in the MERCI trial. The overall mortality rate was 43.5% at 
90 days (n = 138) and, when embolectomy was unsuccess-
ful, the mortality was 54.2%. Mortality dropped to 31.8%, 
however, for those who for whom embolectomy resulted 
in recanalization. In patients with MCA stroke in MERCI, 
mortality was 39% at 90 days compared with 27% in the 
historical control PROACT II placebo arm. Good outcome 
(modiﬁ  ed Rankin less than or equal to 2) was similar for 
both the PROACT II placebo arm and the MERCI trial. In 
the Merci trial, there was an overall mortality rate of 27.7% 
at 90 days. For patients in MERCI who were PROACT-II 
eligible, the mortality rate was 33% compared with a rate 
of 27% in the PROACT-II control arm. For those success-
fully revascularized, a good outcome was seen in 46% of 
patients and for non-revascularized patients, the rate of good 
outcome was 10.4% at 90 days. The authors explained these 
differences by noting that the clinical severity of the MERCI 
trial patients was more severe (NIHSS 19 for MERCI versus 
NIHSS = 17 for PROACT-II) and the vessels treated in the 
MERCI trial were more heterogeneous. The problem of 
this approval process, however, was highlighted by Becker 
and Brott who note that while a clinical trial is underway 
to conﬁ  rm efﬁ  cacy via the MR RESCUE study (Magnetic 
Resonance and Recanalization of Stroke Clots Using Embo-
lectomy) at the same time, a new and improved version of 
the MERCI catheter is being evaluated for approval using 
the same 501K process via a similar non-randomized trial 
(Multi-MERCI) (Becker and Brott 2005). While recanaliza-
tion is an appropriate surrogate endpoint for a Phase II trial, 
clinical outcomes are the desirable measure for intra-arterial 
therapy (Wechsler 2006).
Conclusions
The four examples described above reﬂ  ect the increasing 
interest in procedures to treat acute stroke, promote stroke 
recovery and prevent stroke recurrence. The technological 
imperative in medicine has led to the widespread adoption of 
medical devices and the ﬁ  eld of cerebrovascular disease has 
not been shielded from this explosion in device utilization. 
The issue of efﬁ  cacy versus safety remains unclear however. 
We have seen the limitations of observational studies in many 
pharmaceutical areas. The recent controversy over post-
menopausal hormone replacement whereby a large random-
ized study failed to conﬁ  rm beneﬁ  t seen in older cohort and 
cross-section studies and the failure of vitamin E supplements 
to demonstrate beneﬁ  t in trials of cardiovascular disease or 
cancer are just two examples of the limits of registry type data 
in drug studies (Pham and Plakogeniannis 2005; Hsia 2006). 
Medical devices should be subjected to the same standards 
of safety and efﬁ  cacy as pharmaceuticals. The future offers 
a major opportunity to successfully prevent stroke through 
multi-modality and interdisciplinary approaches. However, 
“just because an attractive procedure is available does not 
mean it should be recommended” (Thomas 2005). There are 
some circumstances where off-label use of medical devices in 
cerebrovascular disease is appropriate. However, we should 
encourage enrollment of patients in randomized studies of 
these devices prior to widespread and routine adoption of a 
procedural approach to cerebrovascular disease. If the device 
approval process continues to not require randomized trials, 
clinical investigators should ‘step up to the plate’ and insist 
that the necessary studies be performed regardless of the 
current approval requirements.
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